Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications.
$99.24-5.80%
报价 2026-11-16
市值
$6.73B
EV
$6.15B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -12.2%
$26.40$113.08
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-16不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ORKAOruka Therapeutics, Inc. | $6.73B | -5.8% | – | 0% | – | – | – | |
| KODKodiak Sciences Inc. | $6.59B | -9.4% | +1783.3% | 0% | – | – | – | |
| XNCRXencor, Inc. | $2.66B | -4.6% | +45.7% | 93.9% | – | – | – | |
| NRIXNurix Therapeutics, Inc. | $1.61B | -4.8% | +749.2% | -139.4% | – | – | 4.4x | |
| URGNUroGen Pharma Ltd. | $1.38B | +7.3% | +185.5% | 90.9% | – | – | – | |
| ANABAnaptysBio, Inc. | $1.36B | -1.1% | -28.8% | 99% | – | 27.8x | 75.2x | |
| RAPPRapport Therapeutics, Inc. Common Stock | $1.19B | -5.1% | 0.0% | 0% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $478M | -3.0% | +80.5% | 80.7% | – | – | – | |
| OCSOculis Holding AG | $471M | -0.1% | – | -2,889.4% | – | – | – | |
| 同行中位数 | – | – | +80.5% | 40.3% | – | 27.8x | 39.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。